EJCRIM 2023 CiteScore
2.1 = | 1.730 Cit. to date |
842 Docs. to date |
Last updated on 05 April, 2024
Updated monthly
Updated monthly
Powered by
Ali Al Sbihi, Nouraldeen Manasrah, Dahlia Sano
2022-03-09
Views: 531
HTML: 122
PDF: 327
|
We present a case series of three multiple myeloma (MM) patients on lenalidomide for maintenance therapy who were at high risk of coronavirus disease 2019 (COVID-19) complications and mortality. However, our patients had minor symptoms after testing positive for COVID-19 although they were unvaccinated. We think that lenalidomide might have a protective effect against severe COVID-19 symptoms.
2.1 = | 1.730 Cit. to date |
842 Docs. to date |
Official Journal of the
European Federation of Internal Medicine
www.efim.org
Publisher: SMC media Srl
Via Giovenale, 7 - 20136 Milan - Italy
P.IVA 07626490960
info@ejcrim.com
www.ejcrim.com - ISSN: 2284-2594 - © EFIM 2014-2023, Published by SMC Media srl, Italy - Privacy policy